RAI, also named ShcC/N-Shc, one of the members of the Shc proteins family, is a substrate of the RET receptor tyrosine kinase. Here, we show that RAI forms a protein complex with both RET/MEN2A and RET/PTC oncoproteins. By coimmunoprecipitation, we found that RAI associates with the Grb2-associated binder1 (GAB1) adapter. This association is constitutive, but, in the presence of RET oncoproteins, both RAI and GAB1 are tyrosine-phosphorylated, and the stoichiometry of this interaction remarkably increases. Consequently, the p85 regulatory subunit of phosphatidylinositol-3 kinase (PI-3K) is recruited to the complex, and its downstream effector Akt is activated. We show that human thyroid cancer cell lines derived from papillary or medullary thyroid carcinoma (PTC or MTC) carrying, respectively, RET/PTC and RET/MEN2A oncoproteins express RAI proteins. We also show that human PTC samples express higher levels of RAI, when compared to normal thyroid tissue. In thyroid cells expressing RET/PTC1, ectopic expression of RAI protects cells from apoptosis; on the other hand, the silencing of endogenous RAI by small inhibitory duplex RNAs in a PTC cell line that expresses endogenous RET/PTC1, increases the rate of spontaneous apoptosis. These data suggest that RAI is a critical substrate for RET oncoproteins in thyroid carcinomas.
Introduction
The family of Shc-like proteins includes three members: Shc, SLI (ShcB/ScK) and RAI (ShcC/N-Shc) (Cattaneo and Pelicci, 1998; Luzi et al., 2000) . It has been shown that while Shc is ubiquitously expressed, the other two members, RAI and SLI, are predominantly expressed in neural tissues (O'Bryan et al., 1996; Pelicci et al., 1996; Nakamura et al., 1998) . In support of their role in the developing brain, it has been shown that null mutations of both RAI and SLI in mice results in a loss of sympathetic neurons. In particular, neurons of the superior cervical ganglia (SCG) are significantly reduced in number in the double-knockout mice, a phenotype that resembles that induced by the knockout of RET tyrosine kinase receptor (Sakai et al., 2000) . Accordingly, we showed that RAI is a physiological substrate of the RET receptor, and that it potentiates RETmediated activation of phosphatydilinositol 3-kinase (PI3-K) and RET-dependent survival of neuronal cells. We also defined the molecular determinants of this interaction, which is mediated by tyrosine 1062 of RET and the phosphotyrosine binding (PTB) domain of RAI (Pelicci et al., 2002) .
The RAI gene codes for two proteins, p64 RAI and p52 RAI, as a consequence of alternative initiation codon usage. These proteins, like the other members of the Shc-like family, share a similar PTB-CH1-SH2 domains modular structure (Luzi et al., 2000; Ravichandran, 2001 ). The PTB and SH2 domains are phospho-tyrosine-recognition modules common to several different proteins with similar functions. The CH1 region contains tyrosine-phosphorylation residues and several SH3 binding sites. For these features, RAI proteins have been implicated in signal transduction mediated by tyrosine kinase receptors (Nakamura et al., 1996; O'Bryan et al., 1998; Pelicci et al., 2002; Liu and Meakin, 2002; Nakazawa et al., 2002) . While RAI and Shc share many common properties, specific features of RAI-mediated signalling have been identified. First, RAI transduces Grb2-SOS-RAS-dependent ERK activation less efficiently than Shc, because it binds less efficiently Grb2. Furthermore, RAI has three novel tyrosine phosphorylation sites that are not present in Shc. These sites represent potential docking sites for signalling adapters, one of which has been identified as the CRK protein. These data implicate that recruitment of RAI may result in specific signalling output and consequent biological activities .
The receptor tyrosine kinase RET is specifically activated by members of the GDNF family of ligands, which are involved in the control of neuronal survival and differentiation, kidney development, and spermatogonial cell fate. These ligands bind RET through GPIanchored coreceptors (Santoro et al., 2004) . RET genetic alterations are responsible for the occurrence of two thyroid malignancies, the medullary (MTC) and the papillary thyroid carcinomas (PTC). These tumors arise, respectively, from the parafollicular C-cells and from the epithelial follicular cells of the thyroid gland. Germline point mutations in RET cause MTC in the context of three related dominantly inherited tumor syndromes, multiple endocrine neoplasia type 2A (MEN2A), multiple endocrine neoplasia type 2B (MEN2B) and familial medullary thyroid carcinoma (FMTC). RET point mutations are also found in a fraction of sporadic MTCs (Santoro et al., 2004) . PTC is the most common endocrine malignancy. In a remarkable fraction of these tumors, chromosomal aberrations involving chromosome 10 are present. Following these aberrations, the intracellular kinase domain of RET is rearranged with heterologous genes, generating the socalled RET/PTC oncogenes (Pierotti, 2001; Nikiforov, 2002) . RET/PTC1 and RET/PTC3 are the most frequent isolates. Both MTC-and PTC-associated RET genetic alterations have a gain-of-function effect, resulting in constitutive kinase activation and oncogenic conversion. Activation of RET either by ligand triggering or by oncogenic conversion initiates most of the signalling pathways activated by tyrosine kinases, such as the RAS/RAF/ERK and the PI3-K/Akt pathways (Santoro et al., 2004) . Several groups have shown the central role of tyrosine 1062 of RET in signal transduction. This residue is the binding site for several different signalling adaptors, such as Shc, RAI, IRS1/2, FRS2, Dok and Enigma (Hayashi et al., 2000) . Activation of PI3-K has been shown to depend on Y1062 of RET through the formation of a Shc/Grb2/GAB1 complex and consequent recruitment and activation of the p85 subunit of the PI3-K (Besset et al., 2000; SegouffinCariou and Billaud, 2000) . Furthermore, it has been shown that GAB1 is necessary not only for Akt activation but also Rac1 activation and lamellipodia formation (Maeda et al., 2004) . In this study, we examined involvement of RAI in human PTC and MTC cell lines derived from these tumor histotypes, by evaluating expression and tyrosine-phosphorylation of this protein. Furthermore, we have studied how RAI couples the PI3-K/Akt pathway to oncogenic RET. We characterized molecular complexes containing RET, RAI and the GAB1 adapter and showed that these complexes lead to the activation of the PI3-K/Akt pathway and cell survival.
Results
An RAI/GAB1 complex links Ret to the p85 subunit of PI3-K and Akt activation
We had previously shown that RAI is able to complex with p85, the regulatory subunit of the PI3-kinase, in vivo, both in the presence and in the absence of RET (Pelicci et al., 2002) . However, the molecular mechanism for p85 recruitment by RAI remains unclear. We had also observed that RAI coprecipitated other phosphoproteins of unknown identity. Among the different phosphoproteins, a band of 115 kDa, a molecular weight compatible with the adapter protein GAB1, was detected (not shown). GAB1 is a likely candidate for p85 recruitment since it has several tyrosine residues that function as docking sites for p85 (Gu and Neel, 2003) . To study whether RAI-recruitment of p85 was indeed mediated by GAB1, we first investigated whether RAI, GAB1 and p85 were able to form stable complexes in vivo. To this aim, we used 293 cells transiently transfected with different combinations of cDNAs encoding RAI, GAB1 and oncogenic RET/MEN2A. In a first set of experiments, we showed a complex between RAI and GAB1 by reciprocal coimmunoprecipitation and Western blotting ( Figure 1a ). This interaction was constitutive, since it occurred also in the absence of RET, but it is strongly potentiated in the presence of RET/MEN2A. Furthermore, RAI and GAB1 are tyrosine-phosphorylated only in the presence of RET/MEN2A (Figure 1a ). To show that also RET/ PTC was able to recruit RAI-GAB1 complex, 293 cells were transiently transfected with RAI, GAB1 and RET/ PTC1. Also, in this case, reciprocal coimmunoprecipitation of RAI and GAB1 showed the presence of a RAI-GAB1 complex, which was enhanced by RET/PTC1 (Figure 1b) . Phosphotyrosine staining of anti-GAB1 immunoprecipitates showed that GAB1 was tyrosinephosphorylated only when RET/PTC1 was coexpressed (data not shown). Since it has been described that Shc recruits GAB through Grb2 (Besset et al., 2000; Segouffin-Cariou and Billaud, 2000) , we asked whether this was also the case for RAI. To this aim, we evaluated the GAB1 ability to bind a mutant of RAI, RAI 3F, in which the consensus sequences for Grb2 (Y304) and Crk binding (Y221, Y222) have been converted to phenylalanine. As shown in Figure 1c , RAI 3F retains the ability to bind GAB1 despite the lack of tyrosine phosphorylation in vivo (not shown). It has been shown that the CH1 domain of RAI has additional tyrosines (Y259, Y260 and Y286) that are sites of phosphorylation in vivo. In particular, Y286 is a binding site for CRK . To investigate whether these tyrosines were involved in RAI/GAB1 interaction, we generated the mutant RAI 6F, derived from RAI 3F, in which we introduced the Y259F, Y260F and Y286F mutations. Also, this mutant retains its ability to bind GAB1, as shown by the coimmunoprecipitation experiment in Figure 1c . Furthermore, these mutants retained their ability to bind GAB1 also in the absence of RET (data not shown). We were unable to detect any Grb2-RAI association in vivo by reciprocal immunoprecipitation, while we could detect both Grb2-Shc and Grb2-GAB1 interactions (not shown).
One of the consequences of p85 recruitment could be the activation of the PI3-K, which leads to the activation of the serine-threonine kinase Akt (Pelicci et al., 2002) . To evaluate whether Akt was activated, 293 cells were cotransfected with RET/PTC1 or RET/MEN2A with RAI in the absence or in the presence of GAB1. The amounts of p85 recruited in the complex were then evaluated by immunoprecipitation with anti-RET, anti-RAI and anti-GAB1 antibodies. Furthermore, the levels of endogenous Akt activation were evaluated by Western blotting with anti-phosphoAkt antibodies. As shown in Figure 1d , the coexpression of RET oncoproteins with RAI induced Akt activation, which was further potentiated when GAB1 was present. GAB1 overexpression also potentiated p85 recruitment ( Figure 1d ).
Molecular determinants of RAI-GAB1 interaction
To investigate the molecular mechanisms underlying the interaction of RAI with GAB1, we performed in vitro binding assays. To this aim, the PTB, CH1 and SH2 domains of RAI were expressed as recombinant GSTfusion proteins in bacteria. Purified proteins were used for pull-down assays in which each GST-protein was incubated with lysates from 293 cells transiently transfected with GAB1 both in the absence and in the presence of activated RET (RET/MEN2A). As shown in Figure 2a , two regions of RAI are involved in GAB1 binding: the CH1 region, which binds GAB1 irrespective of the presence of RET/MEN2A, and the SH2 domain, which binds GAB1 only when it is phosphorylated by RET/MEN2A. These data suggest that the constitutive interaction between RAI and GAB1 observed in the in vivo coimmunoprecipitation experiments ( Figure 1a ) is mediated by the CH1 domain of RAI, and that this interaction can be further stabilized by tyrosine phosphorylation of GAB1 through the engagement of another domain of RAI, the SH2. GAB1 lacks a classical PTB domain, but it contains a noncanonical PTB domain, the so-called MBD or c-Met binding domain, which mediates the interaction with the c-Met receptor. To investigate whether this region of GAB1 is involved in the interaction with RAI, we performed pulldown assays using GST-recombinant proteins fused to either wild-type GAB1 or its MBD domain (GST-GAB1 and GST-MBD). Purified proteins were incubated with cell lysates from 293 cells transfected with RAI both in the absence and in the presence of activated RET (RET/ MEN2A). As shown in Figure 2b , GST-GAB1 was able to recruit RAI, both in the presence and in the absence of RET. This interaction was potentiated when RAI was tyrosine phosphorylated by RET/MEN2A. GST-MBD, on the other hand, was able to bind RAI only when RET/MEN2A was coexpressed. By using anti-RET or antiphosphotyrosine antibodies, RET/MEN2A was always detected in complex with RAI (data not shown). To verify equal loading, the coomassie staining of GSTfusion proteins used for pull-down experiments is shown (Figure 2a and b) .
To assess whether the constitutive interaction between RAI and Gab1 is direct or mediated by other protein adapters, we performed a Far Western overlay assay using recombinant GST-GAB1 fusion protein. 293 cells were transfected with RAI, and RAI immunoprecipitates and total lysates were probed with unphosphorylated GST-GAB1. Consistent with previous data, GST-GAB1 recognized RAI in RAI immunoprecipitates and in total lysates ( Figure 2c ). These data show that RAI and GAB1 are constitutively complexed in the cell and that the constitutive RAI/GAB1 interaction is mediated by the CH1 domain of RAI. To study the role of RAI in thyroid cells, we selected the PC RET/PTC1 rat thyroid cells. This cell line derives from PC Cl 3 rat thyroid epithelial cells, which are a very well established model system to study oncogenic transformation in a thyroid cell setting. Furthermore, these cells express very low levels of endogenous RAI proteins. PC RET/PTC1 cells were transduced with a RAI retroviral vector to obtain the RET/PTC1-RAI cells. RAI and RET/PTC1 expression were verified by immunoblot. We show that also in this system RAI coprecipitated with RET and was constitutively tyrosine-phosphorylated ( Figure 3a) . As a consequence of RAI expression, Akt phosphorylation increased (not shown). We then sought to examine whether RAI induced survival of thyroid cells. Thyroid transformed cells were treated with a strong apoptotic stimulus, diethyl maleate (DEM) (Celetti et al., 2004) . In these conditions, we compared RET/PTC1 to RET/PTC1-RAI cells and the apoptotic rate was evaluated by the terminal desoxynucleotidyl transferase-mediated desoxyuridine triphosphate nick end-labelling (TUNEL) assay, as described (Castellone et al., 2003) . As shown in Figure 3c , RAI overexpression significantly reduced DEM-mediated apoptosis.
We have shown that RAI can recruit the p85 subunit of the PI3-K through GAB1. To investigate whether RAI-GAB1 interaction is required to activate the PI3-K/Akt pathway, and consequently, to induce survival in thyroid cells, we used expression vectors encoding the isolated CH1 and SH2 domains of RAI, RAI CH1 and RAI SH2. We reasoned that the overexpression of these vectors should be able to displace the interaction between RAI and GAB1 by competition with RAI for GAB1 binding. To address this issue, PC RET/PTC1-RAI cells were transiently transfected with RAI CH1 or RAI SH2. As shown in Figure 3b , RAI CH1 and RAI SH2 were able to disrupt the interaction between wildtype RAI and GAB1. As a consequence of this, p85 recruitment by RET/PTC1, and the levels of Akt (Figure 3b ). To verify whether the disruption of RAI-GAB1 interaction resulted in a decreased pro-survival effect in RET/PTC1-RAI expressing cells, we transiently transfected these cells with RAI CH1 or RAI SH2 together with a GFP expressing vector. Transfected cells were treated with DEM, and the rate of apoptotic death was evaluated in GFP-positive cells by TUNEL assay. As shown in Figure 3c , the expression of either RAI CH1 or RAI SH2 inhibited the survival effect exerted by RAI in PC RET/PTC1 cells.
RAI is expressed in human thyroid carcinoma cell lines and in primary PTC
To investigate whether RAI is involved in RETmediated signalling in thyroid tumors in which RET is involved, we screened a series of human cell lines derived from either PTCs or MTCs for RET and RAI expression by Western blot. As a positive control, the MN1, a mouse motoneuron cell line expressing both RET and RAI, was used. As shown in Figure 4a , several PTC and one MTC cell line, coexpressed RAI and the RET oncogenic proteins. In these cells, both the p64 and the p52 isoforms of RAI were detected. A summary of RET and RAI expression status in these cell lines is showed in the table in Figure 4a . Furthermore, by comparing RAI expression in the normal human primary culture (P5) with its expression in TPC cell lines, we verified that RAI is overexpressed in PTC cells. To extend this observation to human tumors we also tested, by Western blot and quantitative PCR, RAI expression in a set of primary tumors from PTC patients and a pool of normal thyroid samples. As shown in Figure 4b , some PTCs samples scored positive for RAI expression. Normal thyroid tissue displayed a lower, but detectable reactivity. To further confirm that RAI is indeed expressed in human thyroid tumors, we extracted total RNAs from a different set of human PTCs and from a pool of 4 normal thyroid tissues, and analysed them by Q-PCR. As shown in Figure 4c , RAI mRNA expression was strongly increased in tumors versus normal thyroids.
To determine whether RAI is involved in RET signalling in human tumors, we analysed, in FB2 and TT cells (derived, respectively, from a papillary and a MTC), anti-RET immunoprecipitates with anti-RAI antibodies, and showed binding of RAI to endogenous Equal amounts of proteins were immunoblotted and stained with anti-RAI mouse monoclonal antibody. As a control for equal loading, filters were stained with the anti-alpha tubulin monoclonal antibody. (b) Human PTCs express high levels of RAI proteins. Tissues from human PTC samples were snap-frozen and immediately homogenized by using the Mixer Mill apparatus (Qiagen) in lysis buffer. Equal amounts of proteins were immunoblotted and stained with anti RAI polyclonal antibodies. As a control for equal loading, the anti-alpha tubulin monoclonal antibody was used. (c) Human PTCs express high levels of RAI mRNA. After RNA extraction, quantitative PCR was used to calculate RAI mRNA fold induction in the indicated tumor samples and in a pool of normal thyroid tissues; results are the average of three independent amplifications7s.d.
Interaction of RET oncoproteins with an RAI(ShcC/N-Shc)-GAB1 complex V De Falco et al
RET/PTC1 and RET/MEN2A (Figure 5a ). Furthermore, by probing anti-RAI immunoprecipitates with anti-phosphotyrosine antibodies, we observed tyrosine phosphorylation of RAI. By using the anti-GAB1 antibodies we detected a 115 kDa protein in RAI immunoprecipitates (Figure 5b) . Furthermore, when GAB1 was immunoprecipitated from FB2 and TT cells, anti-phosphotyrosine antibodies recognized a 52 kDa protein, which was identified by the anti-RAI antibody (Figure 5c ). These data confirm that RAI and RET/PTC interact also when expressed at physiological levels and support the concept that RAI is indeed involved in RET/PTC signalling in human PTCs. To further support the critical role of Gab1 in p85 recruitment and Akt activation by RAI, we depleted FB2 cells of endogenous Gab1 through small interference RNA. As shown in Figure 5d , transient transfection of FB2 cell with human Gab1 small silencing RNA (siRNA) significantly reduced Gab1 levels at 48 h, without affecting RAI and p85 levels. Gab1 knockdown resulted in a reduction of the p85 quantity coprecipitated with RAI, as shown by coimmunoprecipitation experiments. Furthermore, Gab1 knockdown caused the consequent inactivation of Akt, as shown by the staining of the same filters with Akt phospho-specific antibodies (Figure 5d ).
Inactivation of endogenous RAI expression reduces survival of human papillary thyroid cells expressing RET/PTC1
To evaluate the effect of RAI inhibition in human thyroid papillary cancer, we used RNA interference on FB2 cells to deplete endogenous RAI. As shown in Figure 6a , an siRNA duplex oligonucleotide was able to sharply reduce RAI expression, whereas a scrambled oligo did not. On the other hand, RAI siRNA did not inhibit a-tubulin levels. RAI depletion suppressed constitutive Akt activation in FB2 cells (Figure 6a ) while it did not affect endogenous Akt levels (not shown). We performed a TUNEL assay on parental and RAI-depleted FB2 cells. As shown in Figure 6b , RAI depletion induced a significant increase in the number of apoptotic cells after 48 and 72 h. These data suggest that RAI provides a survival signal to this cell line.
Discussion
In this study, we have investigated the role played by RAI in oncogenic RET signalling. We focused on identifying the protein complexes involved in RETmediated PI3-K/Akt activation through RAI. It has been previously shown that RET can indirectly recruit p85 through an Shc-Grb2-GAB1/2 complex. When RET is activated, Shc binds to phosphorylated tyrosine 1062. Grb2 is then recruited by binding a phosphotyrosine in the CH1 of Shc with its SH2 domain. Grb2, in turn, constitutively interacts with GAB1/2 through its SH3 domain, which binds a non canonical polyproline motif in GAB1/2. GAB1/2, in turn, binds the SH2 domain of p85 through several phosphotyrosine residues (Besset et al., 2000; Lock et al., 2000; Schaeper et al., 2000; Lewitzky et al., 2001) . We previously showed that RAI is able to complex with p85 in vivo, both in the presence and in the absence of RET (Pelicci et al., 2002) .
Here, we identify GAB1 as a key mediator of RET/RAI signalling. This protein belongs to a group of docking proteins which includes GAB1/2, IRS1/2, FRS2, and p62 Dok, that function as substrates of tyrosine kinases (Gu and Neel, 2003) . GAB1, in particular, has been identified as a specific substrate of the c-Met receptor. This protein contains a NH 2 -terminal PH domain, a central non canonical phosphotyrosine-binding domain, the MBD, and a carboxyl-terminal domain which contains several tyrosines that serve as docking sites for downstream signalling components, such as p85, PLC-g, Shc, Shp2 and Crk (Gu and Neel, 2003) . Here we show that RAI and GAB1 associate constitutively. This association seems to be mediated by the CH1 domain of RAI, as shown by pull-down assays performed with the GST-CH1 RAI recombinant protein. Given the high degree of conservation between RAI and Shc, we hypothesized that RAI could recruit GAB1 through the adapter Grb2. By coimmunoprecipitation assays and use of RAI mutants we showed that Grb2 was not involved in RAI-GAB1 interaction. Indeed we could demonstrate, by Far Western overlay experiments, that RAI is involved in a direct interaction with GAB1. It is conceivable that overexpression of RAI leads to a stoichiometric recruitment of GAB1, and to the consequent activation of GAB1-mediated signalling pathways, such as PI3-K/Akt. How the recruitment of GAB1 by RAI can trigger GAB1 and activate downstream pathways remains to be solved. One possibility is that RAI binding could localize GAB1 in the proximity of a putative activator. Alternatively, this interaction could exert a conformational change in GAB1, with its consequent activation. The interaction between RAI and GAB1 is potentiated by the presence of activated RET. Indeed, activated RET recruits RAI/GAB1 through its tyrosine 1062 and the PTB domain of RAI (Pelicci et al., 2002) . RAI/GAB1 interaction is further stabilized by tyrosine phosphorylation of both RAI and GAB1, which creates other interaction sites. The RAI SH2 domain possibly recognizes a phosphotyrosine residue in GAB1, and the GAB1 MBD region could bind one of the phosphotyrosines in RAI. Alternatively, GAB1 MBD could bind a novel phosphotyrosine residue in RET. Whatever the case, once GAB1 is phosphorylated, an increased recruitment of p85 on activated RET is observed parallel to an enhanced activation of Akt, and potentiation of cell survival. The relevance of RAI interaction with GAB1 is supported by the experiments with the isolated RAI-CH1 and SH2 domains and by the knockdown of endogenous Gab1, which inhibit downstream signalling events and biological activity. Ectopic expression of RAI in RET/PTC1 expressing rat thyroid cells potentiates the ability of these cells to survive in stress conditions, while depletion of endogenous RAI in FB2 PTC cells increases the rate of spontaneous apoptosis. These data, taken together, suggest a role for this protein in human thyroid tumorigenesis. This is further supported by the observation that RAI and oncogenic isoforms of RET (RET/ PTC1 or RET/MEN2A) are coexpressed in a series of cell lines derived from thyroid malignancies in which RET is involved, PTCs and MTCs. It is interesting to note that RAI expression has been reported to be restricted to the nervous system in post-mitotic neurons (Ganju et al., 1998; Nakamura et al., 1998; Tanabe et al., 1998; Conti et al., 2001) . Despite this, we found expression of RAI in human cell lines derived from human thyroid tumors. While expression of RAI in MTCs is not surprising, since these tumors derive from cells of neural origin, its expression in PTCs, derived from thyroid epithelial cells, is unexpected. It is possible that in these tumors RAI expression is reactivated and that this event is positively selected since it increases the survival of cancer cells. In support of this hypothesis, preliminary data obtained in our laboratory show that RAI expression is also detected in surgical samples of human PTCs by real-time PCR and Western blot. RET/ PTC rearrangements are considered tumor initiating events (Viglietto et al., 1995) . The early events that follow RET/PTC activation do not lead to cell growth, possibly due to concomitant stimulation of DNA synthesis and apoptosis (Castellone et al., 2003; Wang et al., 2003) . RAI overexpression could be an event that PTC cells select to overcome RET/PTC induced apoptosis, thus promoting cancer progression. This is not the only example of RAI involvement in human tumors. Expression and tyrosine phosphorylation of RAI has been found in a large set of neuroblastoma cell lines. In these cells the ALK kinase is overexpressed due to gene amplification, and as a consequence of this, constitutively activated. Activation of ALK was responsible for RAI hyperphosphorylation in these cells (Miyake et al., 2002) . Thus, the role of RAI in human tumors is just starting to be elucidated.
Materials and methods

Cell lines and plasmids
293 cells were maintained in Dulbecco's Modified Eagle's medium (DMEM, Invitrogen Groningen, The Netherlands) supplemented with 10% foetal calf serum. Transient transfections were effectuated with FUGENE reagent, as suggested by the manufacturer (Roche Molecular Diagnostics, Basel, Switzerland). P5 thyroid normal primary culture has been previously described (Curcio et al., 1994) . Human papillary thyroid cancer cell lines TPC-1, FB2, NIM, BHP10-3, BHP17-10, BHP14-9, BC-PAP, BHP2-7, BHP5-16, have been described previously (Cerutti et al., 1996; Ohta et al., 2001; Basolo et al., 2002) , and were maintained in DMEM supplemented with 10% foetal bovine serum, 1% penicillin-streptomicin, and 1% glutamine. Medullary thyroid cancer cell lines TT, MZ-CRC-1 (human), 6-23 (rat), MTC-M (mouse) have also been previously described (Cooley et al., 1995) .
PC Cl 3 is a differentiated thyroid epithelial cell line derived from 18-month-old Fischer rats. They were maintained in Coon's modified F12 medium supplemented with 5% calf serum and six hormones (6H) (thyrotropin, i.e., TSH, insulin, transferrin, somatostatin, hydrocortisone and glycyl-histidyllysine) (Invitrogen, Groningen, The Netherlands) as described (Castellone et al., 2003) . PC RET/PTC1 cells have been previously described (Santoro et al., 1993) . To obtain the PC RET/PTC1-RAI cells, the PC RET/PTC1 cells were infected with a PINCO-RAI virus, as described (Pelicci et al., 2002) . The efficiency of infection, measured as GFP positivity, was evaluated by FACS scanning.
For transient transfections of PC Cl 3 cells, calcium phosphate precipitates were added to the cells and removed after 1 h. Cells were then subjected to glycerol shock and kept in medium containing 5% calf serum and 6H.
Human RET/MEN2A and RET/PTC1 (subcloned into pCDNA 3, Invitrogen) have been previously described (Carlomagno et al., 2001) . RAI and RAI 3F, in which tyrosines 221, 222, 304 were replaced by phenylalanine, expression vectors have been previously described (Pelicci et al., 2002) . To generate RAI 6F, point mutations in Y259, 260 and 286 were introduced into RAI 3F plasmid by using the Quick-change site-directed mutagenesis kit (Stratagene), and verified by sequencing. Plasmids encoding the isolated PTB, CH1 and SH2 domains were obtained by PCR and subcloning into pCDNA 3 vector (Invitrogen). The plasmid encoding GAB1 was a kind gift of S Giordano and P Gual (Institute for Cancer Research and Treatment, University of Torino School of Medicine, Candiolo, Italy).
RNA extraction and real-time PCR
Retrospectively collected archival frozen thyroid tissue samples from patients affected by PTC and normal thyroid tissue samples were retrieved from the files of the Pathology Department of the University of Pisa upon informed consent. Total RNA from the indicated samples was prepared using the RNeasy Midi Kit (Qiagen, Crawley, West Sussex, UK) and subjected to on-column Dnase digestion with the Rnase-free Dnase set (Qiagen, Crawley, West Sussex, UK) following the manufacturer's instructions. The quality of RNA from each sample was verified by electrophoresis through 1% agarose gel and visualization with ethidium bromide.
Random-primed first-strand cDNA was synthesized in a 50 ml reaction volume starting from 2.5 mg RNA by using the GeneAmp RNA PCR Core Kit (Applied Biosystems, Warrington, UK). PCR amplification was performed using the GeneAmp RNA PCR Core Kit system starting from 2 ml of RT product in a reaction volume of 25 ml, according to the manufacturer's instructions. Primers were designed by using a software available at http://www-genome.wi.mit.edu/cgi-bin/ primer/primer3_www.cgi, and synthesized by the MWG Biotech (Ebersberg, Germany). Primer sequences were as follows:
To exclude DNA contamination, each PCR reaction was also performed on untranscribed RNA. Levels of b-actin transcripts served as a control for equal RNA loading. Quantitative (real-time) reverse transcription polymerase chain reactions (qRT-PCR) were performed by using the SYBR Green PCR Master mix (Applied Biosystems) in the iCycler apparatus (Bio-Rad, Munich, Germany). Amplification reactions (25 ml final reaction volume) contained 200 nM of each primer, 3 mM MgCl 2 , 300 mM dNTPs, 1 Â SYBR Green PCR buffer, 0.1 U/ml AmpliTaq Gold DNA polymerase, 0.01 U/ml Amp Erase, RNase-free water, and 2 ml cDNA samples. Thermal cycling conditions were optimized for each primer pair and are available upon request. To verify the absence of nonspecific products, melting curves were performed (80 cycles starting from 551C for 10 s with increments of 0.51C). In all cases, the melting curve confirmed that a single product was generated. Amplification was monitored by measuring the increase in fluorescence caused by the SYBR-Green binding to double-stranded DNA. Fluorescent threshold values were measured in triplicate and fold changes were calculated by the formula: 2
, where DCt is the difference between the amplification fluorescent thresholds of the mRNA of interest and the b-actin mRNA.
Protein studies
Immunoblotting experiments were performed according to the standard procedures. Briefly, cells were harvested in lysis buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1 mM EGTA, 1.5 mM MgCl 2 , 10 mM NaF, 10 mM sodium pyrophosphate, 1 mM Na 3 VO 4 , 10mg of aprotinin/ml, 10 mg of leupeptin/ml) and clarified by centrifugation at 10 000 g. Protein concentration was estimated with a modified Bradford assay (Bio-Rad, Munich, Germany). RET/ PTC3 immunoprecipitation was performed with an anti-RET antibody, as previously described (Santoro et al., 1994) . RAI immunoprecipitation was performed with an anti-RAI rabbit polyclonal antibodies (Pelicci et al., 2002) . Total lysates and immunoprecipitates were separed by SDS-PAGE and then transferred onto nitrocellulose filters (Schleicher & Schuell). Filters were then probed with the indicated antibodies. Antiphosphotyrosine (4G10), anti-p85 and anti-GAB1 antibodies were from Upstate Biotechnology Inc., Lake Placid, NY, USA. Anti-phospho Akt and anti-Akt antibodies were from New England Biolabs, Beverly, MA, USA. Secondary anti-mouse and anti-rabbit antibodies coupled to horseradish peroxidase were from Bio-Rad Inc. Proteins were revealed by an enhanced chemiluminescence detection kit (ECL, Amersham, Bucks, England).
Binding assays and Far Western blotting
Expression vectors for GST-CH1 RAI, GST-SH2 RAI and GST-PTB RAI were generated by cloning the respective domains of RAI, obtained by PCR amplification of the fragments, in the vector pGEX (Pelicci et al., 2002) . GST-GAB1 and GST-MBD were obtained from S Giordano (Institute for Cancer Research and Treatment, University of Torino School of Medicine, Candiolo, Italy). Recombinant proteins were produced in Escherichia coli and purified on glutathione-conjugated sepharose (Amersham). For pull-down assays, 5 mg of the indicated recombinant protein bound to sepharose were incubated with cell lysates 2 h at 41C. After washing the beads, proteins were separed by SDS-PAGE and probed with the indicated antibodies.
For Far Western blotting, total lysates or immunoprecipitates, after SDS-PAGE and blotting on nitrocellulose filters, were first blocked for 2 h in the presence of 10 mM glutathione, and then incubated overnight with purified GST recombinant proteins (1 mg/ml), extensively washed and then developed with anti-GAB1 antibodies.
TUNEL assay
For the TUNEL, an equal number (5 Â 10 3 ) of cells from the different lines was seeded onto single well Costar L-polylisinetreated glass slides. After 24 h treatment with 0.9 mM DEM, cells were fixed in 4% (w/v) paraformaldehyde and, then, they were permeabilized by the addition of 0.1% Triton X-100/ 0.1% sodium citrate. Slides were rinsed twice with PBS, airdried and subjected to the TUNEL reaction (Boehringer, Mannheim). All coverslips were counterstained in PBS containing Hoechst 33258 (final concentration, 1 mg/ml; Sigma Chemical Co.), rinsed in water and mounted in Moviol on glass slides. The fluorescent signal was visualized with an epifluorescent microscope (Axiovert 2, Zeiss) (equipped with a Â 100 objective) interfaced with the image analyser software KS300 (Zeiss). For the experiments of survival inhibition by the isolated RAI domains, PC RET/PTC1 RAI cells were transiently transfected with vectors encoding RAI-CH1 or RAI-SH2 together with a GFP expressing vector, or with GFP alone. After 24 h treatment with 0.9 mM DEM, cells were then subjected to TUNEL reaction, as described. At least 100 GFPpositive cells were counted in five different microscopic fields. For the experiments of survival inhibition in RAI-depleted FB2 cells, FB2 cells were transfected with the siRNA targeting RAI or with the scrambled oligo. At 48 and 72 h posttransfection, cells were fixed for TUNEL reaction.
RNA silencing
Duplex oligonucleotides (Tuschl et al., 1999; Elbashir et al., 2001) , designed with an siRNA selection program available online at http://jura.wi.mit.edu/siRNAext/, were chemically sinthesized by PROLIGO, Boulder, CO, USA. Sense strand for siRNA targeting RAI was the following:
RAIs: 5 0 -GUA CUU GGG GUG CAU UGA AG TT-3 0
The scrambled oligo was 5 0 -AGG AUA GCG UGG AUU UCG GU TT-3
0
The sequences of specific siRNA against human Gab1 were as described (Jin et al., 2005) . For siRNA transfection, FB2 cells were grown under standard conditions. The day before transfection, cells were plated in six-well dishes at 30-40% confluency. Transfection was performed using 5 mg of duplex RNA and 6 ml of Oligofectamine reagent (Invitrogen), as previously described (Hingorani et al., 2003) . Cells were harvested at 48 and 72 h post-transfection.
